跳到主要导航 跳到搜索 跳到主要内容

Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study

  • Kun Liu
  • , Yanping Song
  • , Gezhi Xu
  • , Jian Ye
  • , Zhifeng Wu
  • , Xiaoling Liu
  • , Xiaoguang Dong
  • , Mingzhi Zhang
  • , Yiqiao Xing
  • , Shaoping Zhu
  • , Xia Chen
  • , Yinchen Shen
  • , Hengye Huang
  • , Liyun Yu
  • , Zunhong Ke
  • , Philip J. Rosenfeld
  • , Peter K. Kaiser
  • , Guishuang Ying
  • , Xiaodong Sun
  • , Xun Xu*
  • *此作品的通讯作者
  • Shanghai Gen Hosp
  • Guangzhou Mil
  • Fudan University
  • Army Medical University
  • Nanjing Medical University
  • Wenzhou Medical University
  • Shandong First Medical University & Shandong Academy of Medical Sciences
  • Shantou University
  • Shanghai Jiao Tong University
  • Chengdu Kanghong Biotechnol Inc
  • University of Miami
  • Cleveland Clinic Foundation
  • University of Pennsylvania

科研成果: 期刊稿件 › 论文 › 同行评审

166 引用 (Scopus)

摘要

["PURPOSE: Age-related macular degeneration (AMD) can cause irreversible vision loss leading to blindness. We aim to evaluate the efficacy and safety of intravitreal injections of 0.5 mg conbercept, a new anti vascular endothelial growth factor (anti-VEGF) drug, for treatment of AMD on a schedule more manageable for patients.","DESIGN: A prospective, double-masked, multicenter, sham-controlled, phase III randomized trial.","METHODS: PATIENTS: Patients with choroidal neovascularization (CNV) secondary to AMD were enrolled and randomized to the conbercept group or the sham control group. INTERVENTION: The conbercept group received intravitreal injections of conbercept (0.5 mg) once monthly for the first 3 months, then once quarterly until month 12 (3 + Q3M). The sham group received first 3 monthly sham injections and then 3 monthly injections of conbercept (0.5 mg) followed by quarterly administrations until month 12. MAIN OUTCOME MEASURES: The primary endpoint was mean change from baseline in best-corrected visual acuity (BCVA) at month 3.","RESULTS: A total of 114 patients (91.9%) from 9 sites in China completed the 12-month study. At the 3-month primary endpoint, the mean changes in BCVA from baseline were + 9.20 letters in the conbercept group and + 2.02 letters in the sham group, respectively (P <.001). At 12 months, the mean changes from baseline in BCVA letter score were + 9.98 letters in the conbercept group and + 8.81 letters in the sham group (P =.64). The most common ocular adverse events were associated with intravitreal injections, such as conjunctival hemorrhage, and increased intraocular pressure.","CONCLUSIONS: A conbercept dosing regimen of 3 initial monthly administrations followed by quarterly treatments is effective for treatment of AMD. In previous reports, other anti-VEGF agents were unable to maintain similar clinical benefits with the same regimen. (C) 2018 Elsevier Inc. All rights reserved.)"]
源语言英语
页(从-至)156-167
页数12
期刊American Journal of Ophthalmology
卷197
DOI
出版状态已出版 - 1月 2019

基金资助

THIS WORK WAS SUPPORTED BY CHENGDU KANGHONG BIOTECHNOLOGY INC (CHENGDU, SICHUAN, China). The sponsor participated in the design of the study, conducting the study, data collection, data management, and preparation of the manuscript. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

收录

  • SCIE

学术指纹

探究 'Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study' 的科研主题。它们共同构成独一无二的学术指纹。

引用此